丽珠医药(01513.HK) 公布,公司申报的JP-1366片获国家药品监督管理局核准开展"与适当的抗生素联用以根除幽门螺杆菌"适应症的临床试验。JP-1366片是一款创新钾离子竞争性酸阻滞剂,此前,其用于治疗反流性食管炎适应症的上市申请已于2025年8月获受理;而注射剂型用于治疗消化性溃疡出血的适应症已于2025年10月进入II期临床试验阶段。(de/d)(港股报价延迟最少十五分钟。沽空资料截至...
Source Link丽珠医药(01513.HK) 公布,公司申报的JP-1366片获国家药品监督管理局核准开展"与适当的抗生素联用以根除幽门螺杆菌"适应症的临床试验。JP-1366片是一款创新钾离子竞争性酸阻滞剂,此前,其用于治疗反流性食管炎适应症的上市申请已于2025年8月获受理;而注射剂型用于治疗消化性溃疡出血的适应症已于2025年10月进入II期临床试验阶段。(de/d)(港股报价延迟最少十五分钟。沽空资料截至...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.